Cohera Medical receives U.S. patent titled, ‘Hydrophilic Biodegradable Adhesives’

May 31 2012

Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company patent number 8,182,647, titled "Hydrophilic Biodegradable Adhesives".

The patent relates to a broad platform of novel adhesives including the Company's initial commercial product TissuGlu® Surgical Adhesive, a surgical adhesive used for large flap tissue approximation.  The adhesives covered by the patent are high-strength, completely synthetic and resorbable.  In addition, they have easy application in the operating theatre and are biocompatible for internal human use.  The patent covers variations of adhesives that allow for multiple products with varying strengths and cure properties, thereby enabling the development of products for additional clinical applications. 

"The unique chemistry of these synthetic adhesives is a breakthrough discovery in the field of medical glues," said Eric Beckman, PhD, Chief Scientific Officer of Cohera Medical and the patent's primary inventor.  "The development of this technology has taken many years to perfect, and this patent is the culmination of a significant research effort by the company." 

"We are excited to add this patent to our growing intellectual property portfolio, which solidifies our leadership position in internal surgical adhesives," said Patrick Daly, President and Chief Executive Officer of Cohera Medical. "This patent protects the core of our proprietary technology as well as the key features of our products that make them commercially and clinically viable."

Cohera Medical recently received CE Marking approval for its lead product TissuGlu  and began selling product to hospitals and surgeons in Germany in 2011. TissuGlu has been used successfully in over 350 surgical procedures in Germany by leading plastic and reconstructive surgeons. The product is currently undergoing clinical trials in the U.S.